Inhibitory cell surface proteins on T cells are often dynamically regulated, which contributes to their physiologic function. PECAM-1 (CD31) is an inhibitory receptor that facilitates TGF--mediated suppression of T cell activity. It is well established in CD4 + T cells that PECAM-1 is expressed in naïve recent thymic emigrants, but is down-regulated after acute T cell activation and absent from memory cells. The extent to which PECAM-1 expression is similarly regulated in CD8 + T cells is much less well characterized. We evaluated T cells recovered from mice after infection with a model intracellular pathogen and determined that, in CD8 + T cells, PECAM-1 expression was strongly down-regulated during acute infection but re-expressed to intermediate levels in memory cells. Down-regulation of PECAM-1 expression in CD8 + T cells was transcriptionally regulated and affected by the strength and nature of TCR signaling. PECAM-1 was also detected on the surface of human activated/memory CD8 + , but not CD4 + T cells. These data demonstrate that PECAM-1 expression is dynamically regulated, albeit differently, in both CD4 + and CD8 + T cells. Furthermore, unlike memory CD4 + T cells, memory CD8 + T cells retain PECAM-1 expression and have the potential to be modulated by this inhibitory receptor.
and CD4 + CD45RA + CD31 − central naïve T cells. [7] [8] [9] [10] [11] The majority of CD4 + CD45RA + CD31 + thymic naive T cells contain TCR excision circles (TRECs) and express protein tyrosine kinase-7 (PTK7), and therefore have not undergone proliferation since exiting the thymus, whereas CD4 + CD45RA + CD31 − central naïve T cells do not have TRECs and are thought to comprise cells that have undergone homeostatic proliferation in response to TCR interactions with low affinity self-peptide/MHC complexes. This dichotomy is not perfect, however, since a subset of CD4 + CD45RA + CD31 + cells that lack TRECs [12] [13] [14] and possess a transcriptional profile that is more characteristic of the activated and/or proliferated state of CD4 + CD45RA + CD31 − cells has also been described. 15 Nevertheless, CD31 has come to be widely used as a marker of recent thymic emigrants within the CD4 + CD45RA + T cell population. [15] [16] [17] [18] [19] [20] [21] [22] Importantly, temporal regulation of PECAM-1 expression in T cells other than those that are CD4 + CD45RA + has been much less well studied. Early studies reported that, following its down-regulation in response to TCR stimulation, CD31 remains absent from mature CD4 + T cells throughout subsequent maturation events, including establishment of memory (i.e., CD4 + CD45RA − CD45RO + ). 23, 24 In contrast, among CD8 + T cells, a subset of those that were CD45RA − were found to retain CD31 expression, as did CD45RO + T cells, which expressed CD31 at low to intermediate levels. 23, 24 These findings, which were subsequently largely ignored, suggested that PECAM-1 expression is regulated differently in CD8 + and CD4 + T cells, and that CD8 + memory T cells may retain the potential to be modulated by PECAM-1.
A thorough understanding of how PECAM-1 expression is temporally regulated in CD8 + T cells is crucial for determining the utility of targeting the PECAM-1/TGF R inhibitory axis therapeutically, either alone or in combination with TGF-inhibitors to achieve additive or synergistic effects. We therefore undertook studies to evaluate temporal regulation of PECAM-1 expression in CD8 + T cells. Using mouse models, we found that, similarly to what has been reported for CD4 + T cells, CD8 + T cells express PECAM-1 at high levels in the naïve state and down-regulate it to undetectable levels during acute activation, both after engagement of the TCR in vitro and during acute infection in vivo. Unlike CD4 + T cells, however, memory CD8 + T cells express PECAM-1 at levels that are intermediate between naïve and acutely activated cells. Moreover, human CD8 + , but not CD4 + , T cells that express markers consistent with prior activation also express PECAM-1 at intermediate levels. These data demonstrate that temporal regulation of PECAM-1 expression is different in CD8 + and CD4 + T cells, and that memory CD8 + T cells continue to express PECAM-1, which is unlike memory CD4 + T cells. These findings suggest that, along with CD4 + and CD8 + thymic naive T cells, memory CD8 + T cells may be susceptible to therapeutic strategies designed to target PECAM-1.
MATERIALS AND METHODS

Mice
PECAM-1 −/− mice 25 were backcrossed for >12 generations onto a C57BL/6J background. Wild type and OT-1 C57BL/6J mice were from Jackson Laboratories (Bar Harbor, ME). CD45.1 mice were from NCI-Charles River Laboratories (Frederick, MD). DGK −/− mice were described previously. 26 DGK -/− /OT-I mice were from in-house breeding. Protocols were approved by the Institutional Animal Care and Use Committee of the Medical College of Wisconsin.
Listeria infection
Mice were injected periorbitally with 5000 cfu of Listeria monocytogenes engineered to express ovalbumin (LM-OVA), which contains the H-2K b -restricted T cell epitope SIINFEKL (gift of Michael Bevan, University of Washington). Naïve (CD44 Lo CD62L Hi ), memory (CD44 Hi CD62L Hi ), and activated effector (CD44 Hi CD62L Lo ) CD8 + T cells were purified by FACS from pooled spleen cells 1-4 weeks later. Cells were analyzed for expression of PECAM-1 using antimouse CD31 (11-0311; eBioscience) and for OVA-specific TCRs using H-2K b /SIINFEKL tetramers (gift of John Wherry, University of Pennsylvania). The cell pellets were directly lysed in 2 × SDS gel loading buffer which contained 4% SDS and cell lysates were western blotted using an Ab specific for the PECAM-1 C-terminus (sc-1506-R; Santa Cruz Biotechnology, Santa Cruz, CA 
Evaluation of PECAM-1 expression from RNA-seq data sets of murine LM-OVA infection
Microarray data were retrieved from the Gene Expression Omnibus (GEO) series with GSE15907. 27 The R/Bioconductor package oligo 28 was used for microarray analysis, including background subtraction, quantile normalization, and generation of expression values using the Robust Multi-array Average (RMA) methodology. 
PECAM-1 expression on human T cells
Evaluation of PECAM-1 expression from Microarray data sets
Microarray data were retrieved from GSE23321. 29 GEO2R was used to calculate log2 transformed RMA levels of PECAM-1 expression from microarray data of sorted populations of human naïve (CD3 + CD8 +
and effector memory (CD3 + CD8 + CD45RO + CCR7 − CD45RA − CD62L − ) T cell subsets from peripheral blood of 3 healthy donors. 29 Independent replicates were averaged, and statistical analysis performed as described below.
Statistical analysis
Data were analyzed by two-way ANOVA followed by Bonferroni's multiple comparisons test, one-way ANOVA followed by Tukey's multiple comparison test, or two-tailed Student's t test using GraphPad Prism 6 software (La Jolla, CA).
RESULTS AND DISCUSSION
PECAM-1 is expressed in naïve CD8 + T cells but is down-regulated acutely after activation
The potential for PECAM-1 to function as a regulator of T cell function relies on its expression in T cells. PECAM-1 expression in CD4 + T cell populations is known to be affected by the activation state of the T cell; thus PECAM-1 is expressed at high levels in naïve CD4 + T cells soon after their emigration from the thymus but is subsequently down-regulated after antigen exposure. [7] [8] [9] [10] [11] To determine whether PECAM-1 expression in CD8 + T cells also changes as a function of activation, we infected mice with Listeria monocytogenes-ovalbumin (LM-OVA), which is a bacterial pathogen that generates CD8 + T cell responses to numerous uncharacterized bacterial antigens along with strong responses to ovalbumin. 30 As expected, 31 
PECAM-1 is expressed at intermediate levels in memory CD8 + T cells in mice
In CD4 + T cells, PECAM-1 expression has been shown to be dramatically decreased following activation to levels that are comparably low in acutely activated effector cells and memory cells, which suggests that the down-regulation of PECAM-1 that occurs upon activation of CD4 + T cells is durable. 23, 32, 33 To determine whether the same is true for CD8 + T cells, we evaluated PECAM-1 expression levels on CD8 + T cells recovered from mice 4 weeks after infection with LM-OVA, a time point when formation of memory CD8 + T cell populations is firmly established. 34 PECAM-1 expression remained significantly lower in central memory (CD44 Hi CD62L Hi ) relative to naïve (CD44 Lo CD62L Hi ) CD8 + T cells 4 weeks after infection with LM-OVA ( Fig. 2A,B) . The slightly but significantly lower level of PECAM-1 expression that was observed in central memory CD8 + T cells from infected relative to uninfected mice at 1 week postinfection (Fig. 1A,B ) was no longer present by 4 weeks postinfection ( Fig. 2A,B ), although the slightly lower level of PECAM-1 expression on OVA pos relative to OVA neg central memory CD8 + T cells remained at 4 weeks postinfection (Fig. 2C,D) . The broad distribution of PECAM-1 (Fig. 1A) changed to a bimodal distribution by 4 weeks postinfection ( Fig. 2A) . The PECAM-1 expressing cells within this population were identified as transitional memory (KLRG1 Lo ) cells ( Supplementary Fig. 3 ), which expressed PECAM-1 at levels that were slightly but significantly lower in OVA pos than in OVA neg populations (Fig. 2C,D) . The PECAM-1-negative CD44 Hi CD62L Lo CD8 + T cells 4 weeks after infection were effector memory (KLRG1 Hi ) cells ( Supplementary Fig. 3 ), which failed to express PECAM-1 regardless of OVA specificity (Fig. 2C,D 
Decreased PECAM-1 expression in activated CD8 + T cells is regulated transcriptionally
The mechanism underlying loss of PECAM-1 from the T cell surface after activation is incompletely understood. There is evidence that, in (Fig. 3A) .
Interestingly, Western blot analysis using an Ab specific for the PECAM-1 C-terminus detected only the full-length form of PECAM-1 (apparent MW = 130 kDa), which was present at low, intermediate, and high levels, respectively, in lysates of activated, memory, and naïve CD8 + T cells (Fig. 3B) . In contrast, real-time PCR analysis of mRNA purified from the same populations revealed good correlation between PECAM-1 protein and mRNA levels, in that PECAM-1 mRNA levels were significantly higher in naïve cells relative to both memory and activated cells, and in memory cells relative to activated cells (Fig. 3C) .
As an additional means to evaluate PECAM-1 mRNA levels, we probed a published microarray data set that evaluated gene expression in OVA-specific CD8 + T cells at various time points after infection with LM-OVA, 27 and found good agreement between our data and the previously published analysis in that PECAM-1 mRNA levels declined during acute infection (Fig. 3D, day 8) , before becoming re-expressed at later time points to levels intermediate between naïve and acutely activated T cells (Fig. 3D, day 45 and day 100) . On the basis of these results, we conclude that transcriptional down-regulation, 
PECAM-1 down-regulation in activated CD8 + T cells is mildly affected by TCR ligand affinity
The extent of PECAM-1 down-regulation during acute infection with LM-OVA was slightly more extensive in activated CD8 + T cells bearing and enhances degradation of DAG, which is a second messenger generated in response to TCR ligation. 38 In the absence of DGK , TCR signal strength is increased and the threshold for T cell activation is lowered. 39 Interestingly, DGK deficiency abolished both the effect of CD28 co-stimulation, and the subtle effects of SIINFEKL peptide variant affinity, on the extent to which naïve CD8 + OT-I T cells downregulated PECAM-1 in response to stimulation via the TCR (Fig. 5C,D) . Fig. 6 ). Of note, the IgD6-specific (Fig. 6B) , but not the IgD1-specific ( Supplementary Fig. 6 ), Ab detected higher levels of PECAM-1 on CD45RO − compared to CD45RO + CD8 + T cells, suggesting that naïve, but not activated/memory, human CD8 + T cells express a form of PECAM-1 that possesses membrane-proximal IgD6 and either lacks, or is not recognizable by an Ab specific for, membrane-distal IgD1. Interestingly, in CD45RO + CD8 + cells, the level of PECAM-1 expression was affected by the extent of prior activation in that cells with the highest level of PD-1 expressed PECAM-1 at higher levels than did those with the lowest levels of PD-1 expression (Fig. 6C ). These data indicate that, similar to mice, expression of PECAM-1 differs between CD4 + and CD8 + T cell subsets in humans. To determine whether PECAM-1 mRNA expression varies among human CD8 + T cell subsets, we probed a microarray data set generated by others from sorted populations of naïve, central memory, and effector memory CD8 + T cells. 29 Consistent with our results from flow cytometry, we observed expression of PECAM-1 mRNA in memory CD8 + T cell data sets at levels that were slightly but significantly less than those observed in naïve CD8 + T cell populations (Fig. 6D ). This expression pattern was in contrast to granzyme B, which was only expressed in effector memory subsets, or L-selectin (CD62L), which was only expressed in naïve and central memory subsets (data not shown). Furthermore, there was a statistically insignificant trend toward increased expression of PECAM-1 mRNA in human central memory T cells relative to effector memory T cells (Fig. 6D) , which is consistent with our observation that PECAM-1 is expressed at higher levels in central memory relative to effector memory CD8 + T cell subsets in mice (Fig. 2) . Differences in magnitude of PECAM-1 expression levels between central memory and effector memory CD8 + T cells in humans relative to mice may be attributable to assessment of mRNA vs. protein levels, respectively, or because the effector memory population generated in murine experiments resulted from a recent infection.
In sum, these studies demonstrate that PECAM-1 expression is reg- 
